Varenicline, smoking cessation, and neuropsychiatric adverse events

American Journal of Psychiatry

Volumn 170, Issue 12, 2013, Pages 1460-1467

  Gibbons, Robert D ^a,b   Mann, J John ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE PATCH; PLACEBO; VARENICLINE;

AGGRESSION; AGITATION; ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL HISTORY; MENTAL DISEASE; NAUSEA; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING CESSATION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TOBACCO DEPENDENCE;

EID: 84889028067     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2013.12121599     Document Type: Article

References (17)

1. Cahill K, Stead L, Lancaster T: A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32:119-135
2. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103
3. US Food and Drug Administration (FDA): Information for healthcare professionals: varenicline (marketed as Chantix) and bupropion (marketed as Zyban, Wellbutrin, and generics). Silver Spring, Md, FDA, July 1, 2009. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm
4. Gibbons RD, Mann JJ: Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned? Drug Saf 2011; 34:375-395
5. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S: Suicidal behavior and depression in smoking cessation treatments. PLoS ONE 2011; 6:e27016
6. Tonstad S, Davies S, Flammer M, Russ C, Hughes J: Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010; 33:289-301
7. Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A: A doubleblind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 2011; 69:1075-1082
8. Gunnell D, Irvine D, Wise L, Davies C, Martin RM: Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339:b3805
9. Kasliwal R, Wilton LV, Shakir SA: Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009; 32:499-507
10. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, Brown VL, Engelmann JM, Wetter DW: Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry 2013;70:522-533
11. US Food and Drug Administration (FDA): FDA Drug Safety Communication: Safety review update of Chantix (varenicline)
12. Rosenbaum P, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-50
13. Meyer TE, Taylor LG, Xie S, Graham DJ, Mosholder AD, Williams JR, Moeny D, Quellet-Hellstrom RP, Coster TS: Neuropsychiatric events in varenicline and nicotine replacement patch users in the Military Health System. Addiction 2013; 108:203-210
14. Hedeker D, Gibbons RD: Longitudinal Data Analysis. New York, John Wiley & Sons, 2006
15. Hedeker D, Gibbons RD, Du Toit SHC, Patterson D: SuperMix: A Program for Mixed-Effects Regression Models. Chicago, Scientific Software International, 2008
16. Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42:121-130
17. US Food and Drug Administration (FDA): FDA Adverse Event Reporting System (FAERS) (formerly AERS). Silver Spring, Md, FDA, Sept 10, 2012. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Surveillance/AdverseDrugEffects/ default.htm